Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$425000.0.

  • Cyclerion Therapeutics' Change in Receivables changed N/A to -$425000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100000.0, marking a year-over-year change of. This contributed to the annual value of $556000.0 for FY2024, which is 67916.67% up from last year.
  • Per Cyclerion Therapeutics' latest filing, its Change in Receivables stood at -$425000.0 for Q3 2025.
  • Over the past 5 years, Cyclerion Therapeutics' Change in Receivables peaked at $556000.0 during Q4 2024, and registered a low of -$425000.0 during Q3 2025.
  • In the last 5 years, Cyclerion Therapeutics' Change in Receivables had a median value of -$76000.0 in 2023 and averaged -$12700.0.
  • Per our database at Business Quant, Cyclerion Therapeutics' Change in Receivables tumbled by 11177.69% in 2021 and then soared by 20000.0% in 2022.
  • Over the past 5 years, Cyclerion Therapeutics' Change in Receivables (Quarter) stood at -$285000.0 in 2021, then surged by 54.04% to -$131000.0 in 2022, then rose by 26.72% to -$96000.0 in 2023, then skyrocketed by 679.17% to $556000.0 in 2024, then crashed by 176.44% to -$425000.0 in 2025.
  • Its Change in Receivables was -$425000.0 in Q3 2025, compared to -$56000.0 in Q2 2025 and $25000.0 in Q1 2025.